Related Experiment Videos
Intralesional treatment of basal cell carcinoma with low-dose recombinant interferon gamma
1Department of Dermato-Venereology, Erasmus University, Rotterdam, The Netherlands.
Journal of the American Academy of Dermatology
|October 1, 1989
Abstract:
In this pilot clinical trail the efficacy of intralesional low-dose human recombinant interferon-gamma was investigated in seven outpatients with nodular basal cell carcinoma. There was no antitumor response in any case. Toxic side effects were minimal. All tumors were excised surgically 8 weeks after completion of therapy.